OCTREOTIDE TEVA LP 20 mg, powder and solvent for injectable suspension with extended release bottle, 2 ml
Active ingredients: Octreotide acetate, Octreotide
Commercialized according to BDPMDispensing in France: Prescription only
Powder and solvent for injectable suspension with extended releasebottle, 2 mlintramusculaire
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- OCTREOTIDE TEVA LP 20 mg, poudre et solvant pour suspension injectable à libération prolongée
- Pharmaceutical form
- poudre et solvant pour suspension injectable à libération prolongée
- Route of administration
- intramusculaire
- Presentation description
- 1 flacon(s) en verre - 1 seringue(s) préremplie(s) en verre de 2 ml avec adaptateur avec aiguille(s) sécurisée(s)
- Marketing authorisation holder
- TEVA (PAYS-BAS)
- Reimbursement according to BDPM
- 100 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 15 Jan 2020
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Initial prescription by a hospital doctor
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
65432189CIP73018051CIP133400930180518Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ACÉTATE D'OCTRÉOTIDEpoudre | — | SA |
| OCTRÉOTIDEpoudre | 20,0 mg · un flacon | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.